ATE349226T1 - Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle - Google Patents

Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle

Info

Publication number
ATE349226T1
ATE349226T1 AT99948942T AT99948942T ATE349226T1 AT E349226 T1 ATE349226 T1 AT E349226T1 AT 99948942 T AT99948942 T AT 99948942T AT 99948942 T AT99948942 T AT 99948942T AT E349226 T1 ATE349226 T1 AT E349226T1
Authority
AT
Austria
Prior art keywords
antiplasmin
vivo
ischemic stroke
compounds
sub
Prior art date
Application number
AT99948942T
Other languages
English (en)
Inventor
Nobuo Nagai
Desire Jose Collen
Original Assignee
Leuven Res & Dev Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99202004A external-priority patent/EP1062953A1/de
Application filed by Leuven Res & Dev Vzw filed Critical Leuven Res & Dev Vzw
Application granted granted Critical
Publication of ATE349226T1 publication Critical patent/ATE349226T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
AT99948942T 1998-09-29 1999-09-24 Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle ATE349226T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203280 1998-09-29
EP99202004A EP1062953A1 (de) 1999-06-22 1999-06-22 Verwendung von Verbindungen, die Alpha2-Antiplasmin in vivo reduzieren, zur Herstellung einer Zusammensetzung zur Behandlung ischämischer Schlaganfälle

Publications (1)

Publication Number Publication Date
ATE349226T1 true ATE349226T1 (de) 2007-01-15

Family

ID=26150731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99948942T ATE349226T1 (de) 1998-09-29 1999-09-24 Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle

Country Status (12)

Country Link
US (1) US6946438B1 (de)
EP (1) EP1117437B1 (de)
JP (1) JP4577992B2 (de)
CN (1) CN1191856C (de)
AT (1) ATE349226T1 (de)
AU (1) AU6200599A (de)
CA (1) CA2344317C (de)
DE (1) DE69934595T2 (de)
DK (1) DK1117437T3 (de)
ES (1) ES2276536T3 (de)
HK (1) HK1041449B (de)
WO (1) WO2000018436A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343903B1 (de) 2000-12-21 2007-11-14 Thromb-X N.V. Hefeexpressionsvektor und verfahren zur herstellung eines rekombinanten proteins durch expression in einer hefezelle
AU2003252039A1 (en) 2002-07-23 2004-02-09 Vegenics Limited Methods and compositions for activating or inhibiting vegf-d and vegf-c
CN1961070A (zh) 2004-04-22 2007-05-09 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
JP5539896B2 (ja) * 2007-11-29 2014-07-02 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
WO2009149199A2 (en) * 2008-06-04 2009-12-10 Talecris Biotherapeutics, Inc. Composition, method and kit for preparing plasmin
RU2372086C1 (ru) * 2008-08-06 2009-11-10 Илья Николаевич Медведев СПОСОБ НОРМАЛИЗАЦИИ УРОВНЯ α2 АНТИПЛАЗМИНА ПРИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ С НАРУШЕНИЕМ ТОЛЕРАНТНОСТИ К ГЛЮКОЗЕ
PT2403865E (pt) 2009-03-03 2015-11-18 Grifols Therapeutics Inc Métodos de preparação de plasminogénio
KR20120050442A (ko) 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
US20120189609A1 (en) 2009-08-28 2012-07-26 Thrombogenics Nv Improvement to trabeculectomy
EP2661493B1 (de) 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen- und plasminvarianten
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
AU2012304635B2 (en) * 2011-09-06 2017-08-31 Translational Sciences Inc. SerpinF2-binding molecules and methods of use
ES2982294T3 (es) * 2015-12-18 2024-10-15 Talengen Int Ltd Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus
DK3391902T5 (da) 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
JP6793748B2 (ja) * 2015-12-18 2020-12-02 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 放射性および化学的損傷を予防及び治療するための方法
CN106890325A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
CN108463240A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法
CN108463235A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种用于预防和治疗宫颈糜烂的方法
DK3395354T3 (da) 2015-12-18 2024-06-03 Talengen Int Ltd Plasminogen til anvendelse i behandling af diabetisk nefropati
CN110198732A (zh) 2016-12-15 2019-09-03 泰伦基国际有限公司 一种促进胰岛素受体底物-2表达的方法
US12469605B2 (en) 2019-10-10 2025-11-11 University Of Kentucky Research Foundation Machine learning algorithm for predicting clinical outcomes and identifying drug targets in ischemic stroke
WO2023004626A1 (zh) * 2021-07-28 2023-02-02 北京沙东生物技术有限公司 一种骨髓瘤生物标志物serpinf2及其应用
CN114736948B (zh) * 2022-06-10 2022-11-08 深圳市帝迈生物技术有限公司 一种α2-抗纤溶酶活性测定试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US20030017147A1 (en) 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis

Also Published As

Publication number Publication date
WO2000018436A1 (en) 2000-04-06
DE69934595T2 (de) 2007-10-04
EP1117437A1 (de) 2001-07-25
JP4577992B2 (ja) 2010-11-10
CA2344317C (en) 2012-01-24
CA2344317A1 (en) 2000-04-06
CN1191856C (zh) 2005-03-09
DE69934595D1 (de) 2007-02-08
AU6200599A (en) 2000-04-17
ES2276536T3 (es) 2007-06-16
HK1041449B (zh) 2005-08-19
US6946438B1 (en) 2005-09-20
JP2002525340A (ja) 2002-08-13
EP1117437B1 (de) 2006-12-27
CN1320045A (zh) 2001-10-31
DK1117437T3 (da) 2007-04-10
HK1041449A1 (en) 2002-07-12

Similar Documents

Publication Publication Date Title
ATE349226T1 (de) Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
DE60024649D1 (de) Verbindungen für die behandlung von ischämie
TR200003011T2 (tr) Yeni dihidropirimidinler.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
ITTO950002A1 (it) Trombopoietina.
EP1233770A4 (de) Phosphonatverbindungen
GB9813540D0 (en) Chemical compounds
DE69909775D1 (de) Neue fettanaloge zur behandlung von diabetes
CA2337991A1 (en) Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
YU66000A (sh) Antipikovirusna jedinjenja, njihovo dobijanje i upotreba
NO20006645L (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
DE3870508D1 (de) Zusammensetzung zur behandlung des haares.
ZA975439B (en) New pyridyl alkane acid amides.
DE60021113D1 (de) Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
YU40002A (sh) Antipikornavirusna jedinjenja i kompozicije, njihove farmaceutske upotrebe, i materijali za njihove sinteze
DE69229339D1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE69718469D1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
ATE352310T1 (de) Verwendung von zeoliten zur herstellung oraler zubereitungen zur behandlung von vergiftung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties